Protocol approach 2: gut-focused autoimmune support (BPC-157 plus KPV) Goal: Restore gut barrier integrity and reduce intestinal inflammation Components: BPC-157 : 200-300 mcg twice daily, orally or subcutaneously near the abdomen (promotes mucosal healing, angiogenesis) KPV: 200-500 mcg daily, orally (NF-kB inhibition, cytokine reduction, PepT1-mediated gut absorption) Rationale: For autoimmune conditions with significant gastrointestinal involvement, including IBD, celiac-associated inflammation, or any autoimmune condition complicated by leaky gut, this combination addresses both the physical barrier damage (BPC-157) and the inflammatory signaling (KPV)
One serving (2 capsules) provides a daily dose of 1000 mg
Over these years, studies have demonstrated that OS mediates pathological changes in the brain and blood vessels (Morris et al., 2018) that are closely associated with brain injury and neuro-degenerative diseases
To date, the only human trial involving ipamorelin was just 7 days long [5], which is clearly insufficient to draw any conclusions about this peptide's long-term side effects
